Related Experiment Video
Updated: Jan 23, 2026

Endolymphatic Duct Blockage as a Surgical Treatment Option for Ménière's Disease
Published on: April 28, 2023
Therapeutic Options for Mucopolysaccharidoses: Current and Emerging Treatments
Kazuki Sawamoto1, Molly Stapleton1,2, Carlos J Alméciga-Díaz3
1Nemours Biomedical Research, Nemours/Alfred I. duPont Hospital for Children, 1600 Rockland Rd, Wilmington, DE, 19899-0269, USA.
Abstract:
Mucopolysaccharidoses (MPS) are inborn errors of metabolism produced by a deficiency of one of the enzymes involved in the degradation of glycosaminoglycans (GAGs). Although taken separately, each type is rare. As a group, MPS are relatively frequent, with an overall estimated incidence of around 1 in 20,000-25,000 births. Development of therapeutic options for MPS, including hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT), has modified the natural history of many MPS types. In spite of the improvement in some tissues and organs, significant challenges remain unsolved, including blood-brain barrier (BBB) penetration and treatment of lesions in avascular cartilage, heart valves, and corneas. Newer approaches, such as intrathecal ERT, ERT with fusion proteins to cross the BBB, gene therapy, substrate reduction therapy (SRT), chaperone therapy, and some combination of these strategies may provide better outcomes for MPS patients in the near future. As early diagnosis and early treatment are imperative to improve therapeutic efficacy, the inclusion of MPS in newborn screening programs should enhance the potential impact of treatment in reducing the morbidity associated with MPS diseases. In this review, we evaluate available treatments, including ERT and HSCT, and future treatments, such as gene therapy, SRT, and chaperone therapy, and describe the advantages and disadvantages. We also assess the current clinical endpoints and biomarkers used in clinical trials.
Insights
Mucopolysaccharidoses (MPS) are rare genetic disorders impacting glycosaminoglycan (GAG) metabolism. While treatments like enzyme replacement therapy (ERT) and stem cell transplants exist, challenges like blood-brain barrier penetration remain, necessitating novel therapeutic strategies.
Area of Science:
- Biochemistry
- Genetics
- Metabolic Disorders
Background:
- Mucopolysaccharidoses (MPS) are a group of rare genetic metabolic disorders caused by enzyme deficiencies in glycosaminoglycan (GAG) degradation.
- Individually rare, MPS collectively affect approximately 1 in 20,000-25,000 births.
- Current treatments like hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) have improved outcomes but face limitations.
Purpose of the Study:
- To review existing and emerging therapeutic strategies for Mucopolysaccharidoses.
- To evaluate the advantages and disadvantages of various treatment modalities.
- To assess current clinical endpoints and biomarkers used in MPS research.
Main Methods:
- Literature review of current and novel therapeutic approaches for MPS.
- Analysis of treatment efficacy, challenges, and potential benefits.
- Evaluation of clinical trial endpoints and biomarkers.
Main Results:
- Hematopoietic stem cell transplantation (HSCT) and enzyme replacement therapy (ERT) have shown efficacy but struggle with issues like blood-brain barrier (BBB) penetration and avascular tissue treatment.
- Emerging therapies including intrathecal ERT, BBB-penetrating ERT, gene therapy, substrate reduction therapy (SRT), and chaperone therapy show promise for improved outcomes.
- Early diagnosis and treatment are critical for therapeutic success.
Conclusions:
- Significant challenges persist in treating MPS, particularly regarding BBB penetration and avascular tissues.
- Novel therapeutic strategies offer potential for better patient outcomes in the future.
- Inclusion of MPS in newborn screening programs is crucial for early diagnosis and timely intervention to maximize treatment efficacy.
More Related Videos
Related Concept Videos
Emerging Adulthood
Introduction Cardiac Emergencies
Electrical Current
Therapeutic Index
Applications of GIS: Disaster Management and Emergency Response
Significance of Displacement Current

